Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > I can’t tell if JD is just in denial or delusional
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(285)
•••
Comment by beenthereon Mar 23, 2021 9:34pm
120 Views
Post# 32863918

RE:I can’t tell if JD is just in denial or delusional

RE:I can’t tell if JD is just in denial or delusional zwerp2000 it's quite simple and I am sure you are aware different opinions make a market.

When it comes to BTI there are still those that think BTI is the greatest and going to be a big winner. You could put chrispi in that group.

Then there are investors like you and I who feel BTI has went no where, cannot get their act together, and will be probably  be bought out for pennies on the dollar.

Then there are those that know BTI is a lost cause but try to put an a happy face in hopes that the price would rise enough so they could jump off this dog!

And then you have JD.. the narcissist ... who believes he is always right and he is RIGHT about BTI. He would never concede he was wrong about BTI and most likely go to his grave saying he was right!
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities